Halozyme Therapeutics, Inc. (HALO)

NMS – Цена в реальном времени. Валюта: USD

70.93

+4.52 (6.81%)

При закрытии: May 12, 2026, 4:00 PM EDT

71.93

+1.00 (1.41%)

До открытия: May 13, 2026, 4:00 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Halozyme Therapeutics, Inc. (HALO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Halozyme Therapeutics, Inc. (HALO)

Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up

Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Видео

No Data

Пресс-релизы

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Search stocks

Halozyme Therapeutics, Inc. (HALO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Halozyme Therapeutics, Inc. (HALO)

Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up

Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Видео

No Data

Пресс-релизы

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Halozyme Appoints Darren Snellgrove as Chief Financial Officer